STK11 and non-small cell lung carcinoma: The current findings agree with past studies, as there is supportive evidence from literature that COPB2 knock down undermines survival of KRAS mutant cells, meaning that survival of cells is decreased by the knock down; experiments on non small cell lung cancer (NSCLC) cells show that there is a COPI addiction in KRAS and LKB1 mutated cell lines [48].